The ubiquitinproteasome system and assays to determine responses to inhibitors

Expert Opinion on Drug Discovery

Volumn 5, Issue 12, 2010, Pages 1221-1236

  Tsvetkov, Lyuben ^a   Nanjundan, Meera ^b   Domino, Maria ^a   Daniel, Kenyon G ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

caspase like; chymotrypsin like; protease; proteasome; trypsin like; ubiquitin; ubiquitination

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; DEXAMETHASONE; GEMCITABINE; PROTEASOME; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E1; UBIQUITIN PROTEIN LIGASE E2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CANCER CHEMOTHERAPY; COMPUTER MODEL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; GENE INACTIVATION; GENE SILENCING; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 78649350792     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.530654     Document Type: Review

References (106)

1. Hershko A, Heller H, Elias S, et al. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 1983;258(13):8206-14
2. Handley PM, Mueckler M, Siegel NR, et al. Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. Proc Natl Acad Sci USA 1991;88(1):258-62
3. Jin J, Li X, Gygi SP, et al. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 2007;447(7148):1135-8
4. Li W, Bengtson MH, Ulbrich A, et al. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One 2008;3(1):e1487
5. Li W, Chanda SK, Micik I, et al. Methods for the functional genomic analysis of ubiquitin ligases. Methods Enzymol 2005;398:280-91
6. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009;78:399-434
7. Skowyra D, Craig KL, Tyers M, et al. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 1997;91(2):209-19
8. Bosu DR, Kipreos ET. Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell Div 2008;3:7
9. Pintard L, Willis JH, Willems A, et al. The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. Nature 2003;425(6955):311-16
10. Xu L, Wei Y, Reboul J, et al. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature 2003;425(6955):316-21
11. Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009;10(6):398-409
12. Nijman SM, Luna-Vargas MP, Velds A, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005;123(5):773-86
13. Hofmann RM, Pickart CM. In vitro assembly and recognition of Lys-63 polyubiquitin chains. J Biol Chem 2001;276(30):27936-43
14. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008;9(6):536-42
15. Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 2009;10(5):319-31
16. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79
17. Ingham RJ, Gish G, Pawson T. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene 2004;23(11):1972-84
18. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006;22:159-80
19. Kisselev AF, Goldberg AL. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol 2005;398:364-78
20. Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386(6624):463-71
21. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79(1):13-21
22. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995;7(2):215-23
23. Mearini G, Schlossarek S, Willis MS, et al. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 2008;1782(12):749-63
24. Forster F, Lasker K, Nickell S, et al. Towards an integrated structural model of the 26S proteasome. Mol Cell Proteomics 2010;9(8):1666-77
25. Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat Struct Biol 2003;10(12):980 (Pubitemid 37500485)
26. Smith DM, Daniel KG, Wang Z, et al. Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design. Proteins 2004;54(1):58-70
27. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000;18(2):109-21
28. Groll M, Koguchi Y, Huber R, et al. Crystal structure of the 20S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001;311(3):543-8
29. Schrodinger. SiteMap. 2.4 edition. Schrodinger, LLC, New York, NY; 2010
30. Baumeister W, Walz J, Zuhl F, et al. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998;92(3):367-80
31. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47
32. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999;68:1015-68
33. Kohler A, Cascio P, Leggett DS, et al. The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol Cell 2001;7(6):1143-52
34. Gaedicke S, Firat-Geier E, Constantiniu O, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002;62(23):6901-8
35. Ludwig H, Khayat D, Giaccone G, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005;104(9):1794-807
36. Paul S. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays 2008;30(11-12):1172-84
37. Tseng CW, Monie A, Wu CY, et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med 2008;86(8):899-908
38. Warren G, Grimes K, Xu Y, et al. Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition. Oncol Rep 2006;15(5):1287-91
39. Hegde AN, Upadhya SC. The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci 2007;30(11):587-95
40. Ardley HC. Ring finger ubiquitin protein ligases and their implication to the pathogenesis of human diseases. Curr Pharm Des 2009;15(31):3697-715
41. Vigouroux S, Briand M, Briand Y. Linkage between the proteasome pathway and neurodegenerative diseases and aging. Mol Neurobiol 2004;30(2):201-21
42. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci 2009;100(8):1374-81
43. Lakshmanan M, Bughani U, Duraisamy S, et al. Molecular targeting of E3 ligases-a therapeutic approach for cancer. Expert Opin Ther Targets 2008;12(7):855-70
44. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999;50:57-74
45. Glasgow E, Mishra L. Transforming growth factor-beta signaling and ubiquitinators in cancer. Endocr Relat Cancer 2008;15(1):59-72
46. Inoue T, Kon T, Ajima R, et al. MYO18B interacts with the proteasomal subunit Sug1 and is degraded by the ubiquitin-proteasome pathway. Biochem Biophys Res Commun 2006;342(3):829-34
47. Levy L, Howell M, Das D, et al. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. Mol Cell Biol 2007;27(17):6068-83
48. Nanjundan M, Cheng KW, Zhang F, et al. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol 2008;2(2):164-81
49. Rajan VR, Mitch WE. Muscle wasting in chronic kidney disease: the role of the ubiquitin proteasome system and its clinical impact. Pediatr Nephrol 2008;23(4):527-35
50. Takamatsu H, Yamashita T, Kotani T, et al. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol 2010;91(5):903-6
51. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006;6:129
52. Marfella R, D'Amico M, Di Filippo C, et al. The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc Diabetol 2007;6:35
53. Herrmann J, Soares SM, Lerman LO, et al. Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. J Am Coll Cardiol 2008;51(21):2003-10
54. Rajan V, Mitch WE. Ubiquitin, proteasomes and proteolytic mechanisms activated by kidney disease. Biochim Biophys Acta 2008;1782(12):795-9
55. Bailey JL, Wang X, England BK, et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996;97(6):1447-53
56. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006;5(7):596-613
57. Xu GW, Ali M, Wood TE, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 2010;115(11):2251-9
58. Yang Y, Kitagaki J, Dai RM, et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007;67(19):9472-81
59. Sun Y. Overview of approaches for screening for ubiquitin ligase inhibitors. Methods Enzymol 2005;399:654-63
60. Huang J, Tsvetkov L, Qu K, et al. Approaches to discovering drugs that regulate E3 ubiquitin ligases. Ernst Schering Found Symp Proc 2008(1):153-70
61. Gururaja TL, Pray TR, Lowe R, et al. A homogeneous FRET assay system for multiubiquitin chain assembly and disassembly. Methods Enzymol 2005;399:663-82
62. Swaroop M, Wang Y, Miller P, et al. Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: chip profiling implicates its role in cell cycle regulation. Oncogene 2000;19(24):2855-66
63. Boisclair MD, McClure C, Josiah S, et al. Development of a ubiquitin transfer assay for high throughput screening by fluorescence resonance energy transfer. J Biomol Screen 2000;5(5):319-28
64. Yabuki N, Watanabe S, Kudoh T, et al. Application of homogeneous time-resolved fluorescence (HTRFTM) to monitor poly-ubiquitination of wild-type p53. Comb Chem High Throughput Screen 1999;2(5):279-87
65. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
66. Cardozo T, Abagyan R. Druggability of SCF ubiquitin ligase-protein interfaces. Methods Enzymol 2005;399:634-53
67. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450(7172):1001-9
68. Rao DD, Vorhies JS, Senzer N, et al. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61(9):746-59
69. Kurreck J. RNA interference: from basic research to therapeutic applications. Angew Chem Int Ed Engl 2009;48(8):1378-98
70. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59(2-3):75-86
71. Landen CN Jr, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65(15):6910-18
72. Chen C, Zhou Z, Sheehan CE, et al. Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma. Int J Cancer 2009;124(12):2829-36
73. Li Y, Zhou Z, Alimandi M, et al. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 2009;28(33):2948-58
74. Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res 2009;69(12):4974-82
75. Vinas-Castells R, Beltran M, Valls G, et al. The hypoxia-controlled FBXL14 ubiquitin ligase targets SNAIL1 for proteasome degradation. J Biol Chem 2009;285(6):3794-805
76. Espeseth AS, Huang Q, Gates A, et al. A genome wide analysis of ubiquitin ligases in APP processing identifies a novel regulator of BACE1 mRNA levels. Mol Cell Neurosci 2006;33(3):227-35
77. Stagg HR, Thomas M, van den Boomen D, et al. The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER. J Cell Biol 2009;186(5):685-92
78. Byrne A, McLaren RP, Mason P, et al. Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence. Exp Cell Res 2010;316(2):258-71
79. Peschiaroli A, Skaar JR, Pagano M, et al. The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival. Oncogene 2010;29(9):1384-93
80. Hu XT, Chen W, Zhang FB, et al. Depletion of the proteasome subunit PSMA7 inhibits colorectal cancer cell tumorigenicity and migration. Oncol Rep 2009;22(5):1247-52
81. Kane RC, Farrell AT, Sridhara R, et al. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006;12(10):2955-60
82. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002;6(4):493-500
83. Dou QP, Goldfarb RH. Bortezomib (millennium pharmaceuticals). IDrugs 2002;5(8):828-34
84. Nencioni A, Grunebach F, Patrone F, et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21(1):30-6
85. Daniel KG, Gupta P, Harbach RH, et al. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 2004;67(6):1139-51
86. Ghosh S, Nie A, An J, et al. Structure-based virtual screening of chemical libraries for drug discovery. Curr Opin Chem Biol 2006;10(3):194-202
87. Verdonk ML, Chessari G, Cole JC, et al. Modeling water molecules in protein-ligand docking using GOLD. J Med Chem 2005;48(20):6504-15
88. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30(16):2785-91
89. Schrodinger. Schrodinger Software Suite. Schrodinger LLC, New York; 2006
90. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001;276(16):13322-30
91. Dou QP, Landis-Piwowar KR, Chen D, et al. Green tea polyphenols as a natural tumour cell proteasome inhibitor. Inflammopharmacology 2008;16(5):208-12
92. Daniel KG, Landis-Piwowar KR, Chen D, et al. Methylation of green tea polyphenols affects their binding to and inhibitory poses of the proteasome beta5 subunit. Int J Mol Med 2006;18(4):625-32
93. Mozzicafreddo M, Cuccioloni M, Cecarini V, et al. Homology modeling and docking analysis of the interaction between polyphenols and mammalian 20S proteasomes. J Chem Inf Model 2009;49(2):401-9
94. Basse N, Montes M, Marechal X, et al. Novel organic proteasome inhibitors identified by virtual and in vitro screening. J Med Chem 2010;53(1):509-13
95. Lawrence HR, Kazi A, Luo Y, et al. Synthesis and biological evaluation of naphthoquinone analogs as novel class of proteasome inhibitors. Bioorg Med Chem 2010;18(15):5576-92
96. Brooks WH, Daniel KG, Sung SS, et al. Computational validation of the importance of absolute stereochemistry in virtual screening. J Chem Inf Model 2008;48(3):639-45
97. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 1997;9(6):788-99
98. Chen D, Cui QC, Yang H, et al. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006;66(21):10425-33
99. Daniel KG, Chen D, Orlu S, et al. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005;7(6):R897-908
100. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010;37(1):102-11
101. Petroski MD. The ubiquitin system, disease, and drug discovery. BMC Biochem 2008;9(Suppl 1):S7
102. Scheper J, Guerra-Rebollo M, Sanclimens G, et al. Protein-protein interaction antagonists as novel inhibitors of non-canonical polyubiquitylation. PLoS One 2010;5(6):e11403
103. Tsukamoto S, Takeuchi T, Rotinsulu H, et al. Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis. Bioorg Med Chem Lett 2008;18(24):6319-20
104. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009;15(12):3912-16
105. Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008;90(2):270-83
106. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006;5(9):785-99